[
  {
    "rationale": "HPI clearly lists increased hunger, worry about weight gain, lower home glucose readings, and new ankle swelling since losartan; all stated patient concerns are captured accurately.",
    "satisfaction": 95.0,
    "score": 28.5
  },
  {
    "rationale": "Assessments connect appetite increase to glipizide and edema to losartan, highlight improved glycemic control and resolved cough; edema not explicitly labeled \"adverse effect,\" but implication present.",
    "satisfaction": 85.0,
    "score": 21.25
  },
  {
    "rationale": "Plan instructs daily weight monitoring, reporting of persistent swelling/weight gain, and possible therapy adjustment; mentions general monitoring but omits explicit BG checks and detailed return precautions.",
    "satisfaction": 80.0,
    "score": 16.0
  },
  {
    "rationale": "Only brief diet reminder provided; no discussion of sulfonylurea-related weight gain mechanisms, weight-neutral options, or ARB edema risk.",
    "satisfaction": 40.0,
    "score": 6.0
  },
  {
    "rationale": "Note stays focused on issues in transcript with no extraneous ROS or duplicate material, so minimal penalty required.",
    "satisfaction": 5.0,
    "score": 0.5
  }
]